The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients
Open accessPublished version of a preprint
Abstract
Purpose: We hypothesized that autophagy inhibition would increase response to chemotherapy in the preoperative setting for patients with pancreatic adenocarcinoma. We performed a randomized controlled trial to assess the autophagy inhibitor hydroxychloroquine in combination with gemcitabine and nab-paclitaxel. Patients and Methods: Participants with potentially resectable tumors were randomized to two cycles of nab-paclitaxel and gemcitabine (PG) alone or with hydroxychloroquine (PGH), followed by resection. The primary endpoint was histopathologic response in the resected specimen. Secondary clinical endpoints included serum CA 19-9 biomarker response and margin negative R0 resection. Exploratory endpoints included markers of autophagy, immune infiltrate, and serum cytokines. Results: Thirty-four patients in the PGH arm and 30 in the PG arm were evaluable for the primary endpoint. The PGH arm demonstrated statistically improved Evans grade histopathologic responses (P = 0.00016), compared with control. In patients with elevated CA 19-9, a return to normal was associated with improved overall and recurrence-free survival (P < 0.0001). There were no differences in serious adverse events between arms and chemotherapy dose number was equivalent. The PGH arm had greater evidence of autophagy inhibition in their resected specimens (increased SQSTM1, P = 0.027, as well as increased immune cell tumor infiltration, P = 0.033). Overall survival (P = 0.59) and relapse-free survival (P = 0.55) did not differ between the two arms. Conclusions: The addition of hydroxychloroquine to preoperative gemcitabine and nab-paclitaxel chemotherapy in patients with resectable pancreatic adenocarcinoma resulted in greater pathologic tumor response, improved serum biomarker response, and evidence of autophagy inhibition and immune activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“clinical trials have shown that hydroxychloroquine, which inhibits autophagic flux by preventing lysosomal acidification, enhances PDAC patient response to chemotherapy212,213”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [212]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Pancreatic cancers require autophagy for tumor growth
Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., Bause, A., Li, Y., Stommel, J. M., Dell'Antonio, G., et al. (2011) · Genes & Development · doi:10.1101/gad.2016111 · Cited by 1,498
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Viale, A., Pettazzoni, P., Lyssiotis, C. A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., et al. (2014) · Nature · doi:10.1038/nature13611 · Cited by 1,259
Principles and Current Strategies for Targeting Autophagy for Cancer Treatment
Amaravadi, R. K., Lippincott‐Schwartz, J., Yin, X., Weiss, W. A., Takebe, N., Timmer, W. C., DiPaola, R. S., Lotze, M. T., & White, E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2634 · Cited by 912
Self-citationTranscriptional control of autophagy-lysosome function drives pancreatic cancer metabolism
Perera, R. M., Stoykova, S., Nicolay, B. N., Ross, K. N., Fitamant, J., Boukhali, M., Lengrand, J., Deshpande, V., Selig, M. K., Ferrone, C. R., et al. (2015) · Nature · doi:10.1038/nature14587 · Cited by 799
Preoperative Chemoradiation and Pancreaticoduodenectomy for Adenocarcinoma of the Pancreas
Evans, D. B. (1992) · Archives of Surgery · doi:10.1001/archsurg.1992.01420110083017 · Cited by 771
Guo, J. Y., Karsli-Uzunbas, G., Mathew, R., Aisner, S. C., Kamphorst, J. J., Strohecker, A. M., Chen, G., Price, S., Lu, W., Teng, X., et al. (2013) · Genes & Development · doi:10.1101/gad.219642.113 · Cited by 589
Haeno, H., Gönen, M., Davis, M. B., Herman, J. M., Iacobuzio–Donahue, C. A., & Michor, F. (2012) · Cell · doi:10.1016/j.cell.2011.11.060 · Cited by 412
Yang, A., Herter-Sprie, G., Zhang, H., Lin, E. Y., Biancur, D., Wang, X., Deng, J., Hai, J., Yang, S., Wong, K.-K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0952 · Cited by 349
Breslin, T. M. (2001) · Annals of Surgical Oncology · doi:10.1245/aso.2001.8.2.123 · Cited by 310
Cited by
Sorted by citations
Items 101–200 of 233
Nanomedicine Approaches for Autophagy Modulation in Cancer Therapy
Mahri, S., Villa, R., Shiau, Y., Tang, M., Racacho, K. J., Zong, Q., Chowdhury, S., Hua, T., Godinez, F., Birkeland, A. C., et al. (2025) · Small Science · doi:10.1002/smsc.202400607 · Cited by 20
Oyama, K., Nakata, K., Tsutsumi, C., Hayashi, M., Zhang, B., Mochida, Y., Shinkawa, T., Hirotaka, K., Zhong, P., Date, S., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0830 · Cited by 18
Autophagy and Digestive Disorders: Advances in Understanding and Therapeutic Approaches
Thein, W., Po, W. W., Choi, W. S., & Sohn, U. D. (2021) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2021.086 · Cited by 18
The Role of Stroma in Cancer MetabolismPreprint
Kimmelman, A. C., & Sherman, M. H. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041540 · Cited by 19
Marine-Inspired Drugs and Biomaterials in the Perspective of Pancreatic Cancer Therapies
Fernandes, A. M., Oliveira, C., Reis, R. L., Martins, A. M., & Silva, T. H. (2022) · Marine Drugs · doi:10.3390/md20110689 · Cited by 17
The new insights into autophagy in thyroid cancer progression
Shi, Y., Chen, S., & Liu, R. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04265-6 · Cited by 18
Ding, K., Tian, H., Li, L., Wang, Z., Liu, S., Ding, N., Nice, E. C., Huang, C., Bao, J., Gao, W., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02416-5 · Cited by 17
Prkci Regulates Autophagy and Pancreatic Tumorigenesis in Mice
Inman, K. S., Liu, Y., Scotti, M. L., Leitges, M., Krishna, M., Crawford, H. C., Fields, A. P., & Murray, N. R. (2022) · Cancers · doi:10.3390/cancers14030796 · Cited by 17
Chen, Y., Chen, S.-Y., Li, T., Lin, T., Chen, C., & Yen, G. (2022) · Oncology Letters · doi:10.3892/ol.2022.13248 · Cited by 16
Pharmacokinetic and Pharmacodynamic Assessment of Hydroxychloroquine in Breast Cancer
Eaton, K. M. V., & Gustafson, D. L. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000730 · Cited by 16
Tumors Responsive to Autophagy-Inhibition: Identification and Biomarkers
Barbeau, L. M. O., Keulers, T. G., & Rouschop, K. M. A. (2020) · Cancers · doi:10.3390/cancers12092463 · Cited by 15
Ye, C., Wu, J.-D., Li, L., Sun, S., Wang, Y., Jiang, T.-A., Long, X., & Zhao, J. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01487-w · Cited by 15
Hou, Y. J., Liu, T., Sun, Z., Xu, X., Sun, Z., Li, Z., Liu, J., Tian, S., Li, Y., Zhu, N., et al. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101689 · Cited by 13
Li, J., Zhou, J., Zhao, N., Li, Z., Xu, X., Tang, J., Li, Z., Zhang, X., Wu, Y., Li, Q., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154878 · Cited by 13
Huan, L., Yu, F., Cao, D., Zhou, H., Qin, M., & Cao, Y. (2024) · PLoS ONE · doi:10.1371/journal.pone.0295983 · Cited by 13
Witte, D. P., Pretzell, I., Reißig, T. M., Stein, A., Velthaus, J.-L., Alig, A. H. S., Bohnenberger, H., Knödler, M., Kurreck, A., Sulzer, S., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05954-5 · Cited by 15
Sequestsome-1/p62-targeted small molecules for pancreatic cancer therapy
Cuyler, J., Murthy, P., Spada, N. G., McGuire, T. F., Lotze, M. T., & Xie, X. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.09.011 · Cited by 13
Self-citationGoenka, L., Dubashi, B., Kayal, S., Rajappa, M., Manivannan, P., Chakkalakkoombil, S. V., Gochhait, D., Chaturvedula, L., Pradeep, S., Anandaradje, A., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-01904-w · Cited by 12
Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?
Morris, G., Athan, E., Walder, K. R., Bortolasci, C. C., O'Neil, A. E., Marx, W., Berk, M., Carvalho, A. F., Maes, M. H. J., & Puri, B. K. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118541 · Cited by 12
Zakaria, S., Elsebaey, S., Allam, S., & El‐Sisi, A. E. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113562 · Cited by 11
Ocuin, L. M., Hardacre, J. M., Ammori, J. B., Rothermel, L. D., Mohamed, A., Selfridge, J. E., Bajor, D. J., & Winter, J. M. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.26196 · Cited by 11
Jalouli, M., Harrath, A. H., Al-Zharani, M., & Rahman, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052183 · Cited by 10
Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain
DeLiberty, J. M., Robb, R. N., Gates, C. E., & Bryant, K. L. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.010 · Cited by 10
Marín‐Müller, C., Li, D., Lü, J., Liang, Z., Vega-Martínez, O., Crawford, S. E., Estes, M. K., Fisher, W. E., Chen, C., & Yao, Q. C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082038 · Cited by 10
Yamamoto, K., Iwadate, D., Naito, E., Tateishi, K., & Fujishiro, M. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103012 · Cited by 10
Li, X., Guan, W., Liu, H., Yuan, J., Wang, F., Guan, B., Chen, J., Lu, Q., Zhang, L., & Xu, G. (2024) · APOPTOSIS · doi:10.1007/s10495-024-01956-3 · Cited by 10
Hashimoto, A., & Hashimoto, S. (2024) · Cancers · doi:10.3390/cancers16234094 · Cited by 11
Trentini, F., Agnetti, V., Manini, M., Giovannetti, E., & Garajová, I. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1499414 · Cited by 10
Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions
Peng, C., & Oberstein, P. E. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01352-2 · Cited by 14
Zhang, Y., Ji, Y., Tu, Y., & Li, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1642050 · Cited by 10
Watson, M. D., Thompson, K. J., Musselwhite, L. W., Hwang, J. J., Baker, E. H., Martinie, J. B., Vrochides, D. V., Iannitti, D. A., & Ocuin, L. M. (2020) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2020.10.030 · Cited by 10
Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer
Gorgulho, C. M., Krishnamurthy, A., Lanzi, A., Galon, J., Housseau, F., Kaneno, R., & Lotze, M. T. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000357 · Cited by 12
Self-citationFuture of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far
Wong, W., Alouani, E. L., Wei, A. Z., Ryu, Y. K., Chabot, J. A., & Manji, G. A. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.007 · Cited by 10
Lin, S., Han, C., Lou, X., & Wu, Z. B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.955100 · Cited by 10
Zhu, T., Wu, X., Liao, Y., Yan, Y., Yu, M., Wang, L., & Xia, Q. (2023) · Clinical Cancer Bulletin · doi:10.1007/s44272-023-00005-5 · Cited by 8
Different Cytotoxic Effects of Cisplatin on Pancreatic Ductal Adenocarcinoma Cell Lines
Muscella, A., Cossa, L. G., Stefàno, E., Rovito, G., Benedetti, M., Fanizzi, F. P., & Marsigliante, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413662 · Cited by 9
Gong, T., Han, Q., Zhang, Y., Zhu, K., Chen, Y., Tao, Y., Xing, H., Wu, D., Ma, Y., & Zhang, S. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214401 · Cited by 9
Crosstalk between lipid droplets and autophagy in cancer: A nexus for therapeutic targeting
Li, X., Zhang, J., Luo, S., Yu, X., & Song, C. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108023 · Cited by 9
Botelho, M. S., Bolfi, F., Leite, R. G. O. F., Leite, M. S. F., Banzato, L. R., Soares, L. T., Olivatti, T. O. F., Mangolim, A. S., Oliveira, F. R. K., Abbade, L. P. F., et al. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01835-x · Cited by 9
Long Non-Coding RNAs and Metabolic Rewiring in Pancreatic Cancer
Dalmasso, B., & Ghiorzo, P. (2023) · Cancers · doi:10.3390/cancers15133486 · Cited by 9
Lee, S. M., Hewish, M., Ahmed, S. I., Papadatos-Pastos, D., Karapanagiotou, E. M., Blackhall, F. H., Ford, A. M., Young, R., Garcia, A., Arora, A., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115162 · Cited by 8
Zhang, Z., Chen, Q., Zheng, R., Shao, Z., Wei, X., Gu, X., Zang, Y., Yang, X.-S., Wu, J., Dai, M., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114187 · Cited by 8
KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
Tang, D., Kroemer, G., & Kang, R. (2025) · BMJ Oncology · doi:10.1136/bmjonc-2025-000946 · Cited by 12
Self-citationAutophagy modulation in cancer
Guilbaud, E., Ryan, K. M., Green, D. R., & Galluzzi, L. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01449-9 · Cited by 11
Kuang, Y., Ye, N., Kyani, A., Ljungman, M. E., Paulsen, M. T., Chen, H., Zhou, M., Wild, C., Chen, H., Zhou, J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02207 · Cited by 8
Zhou, X., He, Y., Liu, D., Lin, C.-R., Liang, D., Huang, R., & Wang, L. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.862179 · Cited by 8
Tu, N., Shen, X., Deng, S., Xie, Y., Liu, H., Li, H., Li, N., & Mei, L. (2023) · ACS Applied Nano Materials · doi:10.1021/acsanm.3c04532 · Cited by 8
Hydroxychloroquine reduces IL-6 and pro-thrombotic status
Sciascia, S., Schreiber, K. I., Radin, M., Roccatello, D., Krämer, B. K., & Stach, K. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102555 · Cited by 8
PPM1G promotes autophagy and progression of pancreatic cancer via upregulating HMGB1
Song, M., Xu, M., Zhang, Q., Fan, T., Xu, J., Cheng, H., Cheng, C., Ou, X., Chen, G., & Lu, Q. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111342 · Cited by 7
Ye, D., Zhou, S. Y., Dai, X., Xu, H., Tang, Q., Huang, H., & Bi, F. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189161 · Cited by 8
Autophagy: The convergence point of aging and cancer
Pandey, A., Goswami, A., Jithin, B., & Shukla, S. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.101986 · Cited by 7
Hsieh, C.-H., Huang, Y., & Tsai, T. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00713-1 · Cited by 7
Trends in metabolic signaling pathways of tumor drug resistance: A scientometric analysis
Jiang, R., Cao, M., Mei, S., Guo, S., Zhang, W., Ji, N., & Zhao, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.981406 · Cited by 8
Nonoyama, K., Matsuo, Y., Sugita, S., Eguchi, Y., Denda, Y., Murase, H., Kato, T., Imafuji, H., Saito, K., Morimoto, M., et al. (2024) · Cancer Science · doi:10.1111/cas.16173 · Cited by 7
Advances in Drug Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
Gao, J., Wang, J., Guan, C., Shi, W., Dong, Q., Sheng, J., Zou, X., Xu, Z., Ge, Y., Huang, Z., et al. (2024) · Journal of Cancer · doi:10.7150/jca.89788 · Cited by 7
Spatio-temporal processes in autophagosome-lysosome fusion
Liu, S., Yan, H., Diao, J., Zhang, S., & Zhong, Q. (2025) · Medical Review · doi:10.1515/mr-2024-0095 · Cited by 6
Targeting SIRT1 by Scopoletin to Inhibit XBB.1.5 COVID-19 Life Cycle
Sotoudeheian, M., Mirahmadi, S., Pirhayati, M., Farahmandian, N., Azarbad, R., & Pazoki–Toroudi, H. (2024) · Current Clinical Pharmacology · doi:10.2174/0127724328281178240225082456 · Cited by 6
Surana, R., Morgado, M., Somasundaram, A., Bockorny, B., Weekes, C. D., Coleman, E. C., Bird, A., Wang, J., Williams, H. L., Zheng, H., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00332 · Cited by 9
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
Coukos, G., Donia, M., Gastman, B., Goff, S. L., Gros, A., Harari, A., Hernandez, S., Ito, F., Maker, A. V., Mullinax, J. E., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013420 · Cited by 7
Self-citationZhang, H., Yan, H., Liu, Y., Zeng, A., & Song, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1722559 · Cited by 5
O'Reilly, E. M., Cabanski, C. R., Lyman, J. P., Wainberg, Z. A., Fisher, G. A., Wolff, R. A., Ko, A. H., O’Hara, M. H., Spencer, C. N., Yu, J. X., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012864 · Cited by 5
Self-citationTsukamoto, S., Huaze, Y., Weisheng, Z., Machinaga, A., Kakiuchi, N., Ogawa, S., Seno, H., Higashiyama, S., Matsuda, M., & Hiratsuka, T. (2024) · Cancer Science · doi:10.1111/cas.16439 · Cited by 5
TYRO3 promotes chemoresistance via increased LC3 expression in pancreatic cancer
Hara, K., Horikoshi, Y., Morimoto, M., Nakaso, K., Sunaguchi, T., Kurashiki, T., Nakayama, Y., Hanaki, T., Yamamoto, M., Sakamoto, T., et al. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101608 · Cited by 5
Li, H., Zhang, C., Zhu, N., Shi, Y., & Li, Q. (2024) · Journal of Cancer · doi:10.7150/jca.103708 · Cited by 5
Selective Autophagy Conceals the Enemy: Why Cytotoxic T Cells Don’t (MH)C Pancreatic Cancer
Božić, M., & Wilkinson, S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.06.009 · Cited by 5
Mazloomnejad, R., Ahmadi, A., Piroozkhah, M., Omranian, A. Z., Zabihi, M. R., Mojarad, E. N., Kavousi, K., & Salehi, Z. (2023) · Research Square · doi:10.21203/rs.3.rs-2823707/v1 · Cited by 5
Osthole induces accumulation of impaired autophagosome against pancreatic cancer cells
Weng, N., Lv, S., Chen, H., Zheng, H., Tong, L., Zhu, Q., Zhu, K., & Huang, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-81911-z · Cited by 4
Altalbawy, F. M. A., Theab, E. Y., Sanghvi, G. V., Roopashree, R., Kashyap, A., Al‐Hetty, H. R. A. K., S, G. S., Panigrahi, R., Mustafa, Y. F., & Yasin, H. A. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152397 · Cited by 7
Crosstalk Between Autophagy and Paraptosis: A New Frontier in Cancer Therapy
Hanson, S., Murugan, D., Jinsha, P. V., Binoy, A., Nair, B. G., & Mishra, N. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052234 · Cited by 4
Niemann, B. R., Rao, P., Hopen, Q., Landreth, K. M., Basnet, A., Geldenhuys, W. J., Liu, T. W. B., & Boone, B. A. (2025) · Journal of Inflammation · doi:10.1186/s12950-025-00456-8 · Cited by 4
Self-citationMysona, D., Tran, L. K. H., Bai, S., dos Santos, B., Ghamande, S. A., Chan, J. K., & She, J. (2021) · PubMed Central · Cited by 4
Plant natural products as autophagy modulators to improve potential cancer therapy
Fu, L., Liu, C., Zhang, J., & Yu, H. (2023) · Studies in natural products chemistry · doi:10.1016/b978-0-323-91294-5.00010-5 · Cited by 4
Al‐Bari, M. A. A. (2022) · All Life · doi:10.1080/26895293.2022.2078894 · Cited by 4
Song, M., Lu, Q., Xu, M., Li, Y., Zhao, Y., Chen, G., & Ou, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.987026 · Cited by 4
Therapeutic Targeting of Autophagy in Pancreatic Cancer
Foth, M., Garrido‐Laguna, I., & Kinsey, C. G. (2021) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2021.06.001 · Cited by 4
The role of autophagy in pancreatic diseases
Zhang, W., Wu, Q.-Z., & Shao, B. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1444657 · Cited by 4
Autophagy in cancer and protein conformational disorders
Attanasio, S. (2025) · FEBS Letters · doi:10.1002/1873-3468.70061 · Cited by 5
Bandi, D. S. R., Sarvesh, S., Foote, J. B., Welsch, D., Cheng, C., Akce, M., Nagaraju, G. P., & El‐Rayes, B. F. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00967-9 · Cited by 3
The Dual Role of Autophagy in Cancer: Mechanisms and Therapeutic Strategies
Gao, X.-Z., Qin, Y., Wan, H., Lu, G. X., & Shen, H. (2026) · MedComm – Oncology · doi:10.1002/mog2.70064 · Cited by 3
Dichotomous role of autophagy in cancer
Arif, A., Khawar, M. B., Mehmood, R., Abbasi, M. H., & Sheikh, N. (2022) · Asian Biomedicine · doi:10.2478/abm-2022-0014 · Cited by 4
Zhou, X., Zhang, S., Ou, M., Tao, H., Cao, T., Li, L., Zhang, G., & Lu, H. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiaf095 · Cited by 3
Autophagy in Cancer Therapy: Advances and Prospects
Borhani, S. (2023) · Current Molecular Biology Reports · doi:10.1007/s40610-023-00151-8 · Cited by 3
Murthy, P., Zenati, M. S., AlMasri, S. S., DeSilva, A., Singhi, A. D., Paniccia, A., Lee, K. K. W., Simmons, R. L., Bahary, N., Lotze, M. T., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7070 · Cited by 5
Self-citationTeng, Y., Xing, Y., Xue, W., Hu, Y., Li, Z., Qian, J., & Wang, R. (2024) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2024.07.004 · Cited by 3
Lin, E. Y., Mukhopadhyay, S., Corcoran, D., Assi, M., Encarnación-Rosado, J., Sohn, A. S. W., Biancur, D. E., Yu, P. Y., Deng, J., Chen, T., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-2451 · Cited by 2
Autophagy-Targeted Nanoparticles for the Treatment of Cancer
Machhindra, K. S., Mane, R., Kumar, A., & Yadav, A. K. (2024) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-66421-2_9 · Cited by 2
Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials
Kang, B. W., & Chau, I. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1995354 · Cited by 2
Marukawa, D., Gotoh, K., Kobayashi, S., Sasaki, K., Iwagami, Y., Yamada, D., Tomimaru, Y., Akita, H., Asaoka, T., Noda, T., et al. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02306-0 · Cited by 2
Zhu, X., Cao, Y., & Zhang, H. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00529-5 · Cited by 2
GOT2: New therapeutic target in pancreatic cancer
Bu, J., Miao, Z., & Yang, Q. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101370 · Cited by 1
The crosstalk between MiRNAs and autophagy in leukemia: mechanisms and therapeutic insights
Beyrami, A. F., Akbari, A. A. M., Maleki, L. A., Dolati, S., & Yousefi, M. (2025) · Discover Oncology · doi:10.1007/s12672-025-03686-7 · Cited by 2
Enhancing radiation sensitivity in malignant brain tumors with chloroquine: a systematic review
Harary, P. M., Hori, Y. S., Annagiri, S., Abe, K., Tatekoshi, Y., Hosoda, R., Saga, Y., Park, D. J., Kuno, A., & Chang, S. D. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-05362-w · Cited by 1
Wang, Z., Lyu, Z., Palmen, R., Bao, Q., Popp, F., Dong, Q., Bruns, C. J., & Zhao, Y. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-02948-9 · Cited by 1
Mechanism of ASIC4 in regulating MHC-I-mediated immune evasion in pancreatic cancer
An, Q., An, Z., Bo, W., Yan, C., Sun, N., Ma, J., Li, J., & Wang, W. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07880-1 · Cited by 2
Artificial intelligence: Catalyzing a new era in pancreatic cancer cure
Wang, J., Luo, W., Zhang, M., Wang, Y., Ye, L., Qiu, J. U. N. T. A. O., Liu, Y., Weng, G., Liu, T., Cao, Z., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218558 · Cited by 1
Regulated cell death programs shaping cancer therapy
Luo, H., & Guo, Y. (2026) · Cellular Oncology · doi:10.1007/s13402-026-01232-3 · Cited by 1
Jeram, N. M., Senjor, E., Kos, J., & Nanut, M. P. (2026) · Biomolecules · doi:10.3390/biom16060824 · Cited by 1
Gustafson, D. L., Viola, L., Towers, C. G., Das, S., Duval, D. L., & Eaton, K. M. V. (2023) · Veterinary and Comparative Oncology · doi:10.1111/vco.12937 · Cited by 1
Yao, Z., Zhang, H., Huang, K., Huang, G., Xi, P., Jiang, L., Qin, D., Chen, F., Li, S., & Wei, R. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102206 · Cited by 1
Recent Advancement in Drug Targeting Therapies in the Treatment of Pancreatic Cancer
Harwansh, R. K., Hamid, J. A., Wal, P., Deshmukh, R., Patra, P. K., & Gasmi, A. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128334659241223113743 · Cited by 2
Metadata
- Authors
- Zeh, H. J., Bahary, N., Boone, B. A., Singhi, A. D., Miller-Ocuin, J. L., Normolle, D. P., Zureikat, A. H., Hogg, M. E., Bartlett, D. L., Lee, K. K., Tsung, A., Marsh, J. W., Murthy, P., Tang, D., Seiser, N., Amaravadi, R. K., Espina, V., Liotta, L., & Lotze, M. T.
- Affiliations
- University of Pittsburgh (US)
- St Vincent Medical Center (US)
- University of Pennsylvania (US)
- George Mason University (US)
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2020-07-01
- Volume
- 26
- Issue
- 13
- Pages
- 3126-3134
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC8086597
- OpenAlex
- W3010751808
- Cited by
- 233
- References
- 34
- Citations by year
- 2026: 31 · 2025: 34 · 2024: 33 · 2023: 43 · 2022: 36 · 2021: 38 · 2020: 18
- FWCI
- 12.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH (1R01 CA181450, R01GM115366, R01CA206012)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic ductal adenocarcinoma, autophagy inhibition, hydroxychloroquine, gemcitabine, nab-paclitaxel, neoadjuvant chemotherapy, resectable pancreatic cancer, CA19-9, p62, tumor-infiltrating immune cells, R0 resection, overall survival, relapse-free survival
- MeSH terms
- Gemcitabine, Adult, Aged, Aged, 80 and over, Albumins, Antineoplastic Combined Chemotherapy Protocols, Autophagy, Deoxycytidine, Female, Humans, Hydroxychloroquine, Male, Middle Aged, Neoplasm Staging, Pancreatic Neoplasms, Preoperative Care, Recurrence, Survival Analysis, Treatment Outcome, Paclitaxel, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
